REGULATORY, HTA & EVIDENCE STRATEGY

Approval is not enough if the evidence cannot support access

Align regulatory interactions, payer relevance and lifecycle evidence before requirements diverge.

The problem

Regulatory and payer evidence are often planned on different clocks

A development plan can satisfy an approval pathway yet leave comparator, meaningful-benefit, quality-of-life, resource-use or transferability questions unanswered. Late repair is expensive and sometimes impossible.

What we do

Build one traceable evidence strategy

FDA and EMA pathway and interaction strategy
Scientific advice, briefing-book and meeting preparation
Pediatric, rare-disease and accelerated-pathway planning
HTA, HEOR, payer and value-evidence requirements
Comparator, endpoint and meaningful-benefit challenge
RWE and lifecycle evidence architecture
Clear distinction between required, valuable and non-priority evidence

Best fit

Use this mandate when evidence must serve several decisions

Before major agency or scientific-advice interactions
Before pivotal design is locked
When HTA and payer needs entered the program too late
When a rare-disease or accelerated pathway requires explicit uncertainty management
When clinical, regulatory and access teams need one evidence map

Connect evidence to design and adoption

A decision-grade next step

Align approval, access and adoption before the trial is locked.

Make every evidence requirement explicit, prioritized and traceable.